UroGen Pharma Ltd (nasdaq:URGN) Share Price

Company Profile

Business description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Contact
400 Alexander Park Drive
4th Floor
PrincetonNJ08540
USA
T: +1 646 768-9780
E: [email protected]
https://www.urogen.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
291

Recommended

With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.

Dan Romanoff, CPA | 08 May 2026

Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.

Seth Goldstein, CFA | 08 May 2026

With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.

Jacob Robbins | 08 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,980.50	31.60	-0.35%
CAC 40	8,112.57	89.51	-1.09%
DAX 40	24,338.63	324.98	-1.32%
Dow JONES (US)	49,609.16	12.19	0.02%
FTSE 100	10,233.07	43.88	-0.43%
HKSE	26,393.71	232.57	-0.87%
NASDAQ	26,247.08	440.88	1.71%
Nikkei 225	62,713.65	120.19	-0.19%
NZX 50 Index	13,175.13	95.48	-0.72%
S&P 500	7,398.93	61.82	0.84%
S&P/ASX 200	8,744.40	36.40	-0.41%
SSE Composite Index	4,179.95	0.14	-0.00%